文献速递乳腺癌放疗姑息放疗与转移瘤

OLIGOMA试验:寡转移乳腺癌标准全身治疗联合转移灶定向放疗的随机对照研究方案

Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA).
PubMed 文献 · Clin Transl Radiat Oncol · 2021-04-05

OLIGOMA是一项随机对照多国多中心确证性试验,研究在寡转移乳腺癌患者中,标准全身治疗基础上加用对所有转移灶的局部消融放疗的疗效。患者按1:1随机分组,共同主要终点为无进展生存期和12周生活质量。研究旨在提供局部消融放疗在此人群中的高级别证据。

要点

  • 入组最多5个转移灶的寡转移乳腺癌,包括最多3个脑转移(仅限有颅外病灶时)。
  • 共同主要终点为无进展生存期和随机化后12周生活质量非劣效。
  • 标准组允许对症状性转移灶行姑息放疗,但至少一个病灶需未治疗。

核心结论

  • OLIGOMA试验旨在确证标准全身治疗联合局部消融放疗能否改善寡转移乳腺癌患者的无进展生存期并保持生活质量非劣效。

研究设计与样本

  • 随机对照多国多中心确证性试验,患者按1:1随机分配至标准全身治疗联合或不联合对所有转移灶的放疗。
  • 随机化按全身治疗类型和线数分层,治疗前需经多学科肿瘤委员会确定。
  • 入组标准为最多5个转移灶,包括最多3个脑转移(仅限有颅外病灶时)和局部区域复发(仅限有额外转移灶时)。

关键数值与推荐

  • 共同主要终点为无进展生存期和随机化后12周生活质量。
  • 主要假设为试验组无进展生存期优于标准组,同时证明12周生活质量非劣效。
  • 次要终点包括可行性、总生存期、毒性、生活质量和患者满意度。
  • 标准组允许对症状性转移灶行姑息放疗,但至少一个病灶需未治疗。
  • 将进行收集ctDNA的转化亚研究。

临床怎么用

  • 该试验结果将为寡转移乳腺癌患者是否在标准全身治疗基础上加用转移灶定向局部消融放疗提供高级别证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several recent randomized therapeutic exploratory trials demonstrated improvement of progression-free survival and in some even overall survival using stereotactic body radiotherapy in patients with oligometastatic disease. However, only very few patients enrolled in these trials had breast cancer, and results from confirmatory trials are lacking. METHODS/DESIGN: The OLIGOMA-trial is a randomized controlled multi-national multi-center therapeutic confirmatory trial studying the role of local ablative radiotherapy as an additive treatment in patients with oligometastatic breast cancer receiving standard systemic therapy. Patients will be randomized 1:1 to standard systemic therapy according to national guidelines with or without radiotherapy to all metastatic sites. Randomization will be stratified according to type and line of systemic therapy, which has to be determined by a multidisciplinary tumor board before enrollment. Patients with up to five metastatic lesions are eligible, including patients with up to three brain metastases (only in case of extracranial disease) and with locoregional recurrence (only in case of additional metastatic lesions). In the standard arm, palliative radiotherapy to symptomatic metastases is permitted if at least one lesion remains untreated. The co-primary endpoints are progression-free survival and quality of life. The primary hypothesis is that progression-free survival in the experimental arm will be superior to the standard arm while simultaneously demonstrating non-inferiority of quality of life at 12 weeks after randomization. Secondary endpoints are feasibility, overall survival, toxicity, quality of life and patient satisfaction. A translational sub-study with collection of ctDNA will be conducted. DISCUSSION: The OLIGOMA-trial will provide high level evidence on the use of and benefit from local ablative radiotherapy for patients with oligometastatic breast cancer. TRIAL REGISTRATION: The OLIGOMA-trial is registered at clinicialtrials.gov under the identification NCT04495309. The related information was first posted on July 31st 2020.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Krug D, Vonthein R, Illen A, et al. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021. PMID: 33912695. doi:10.1016/j.ctro.2021.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。